

# PREVENIR 5 - Persistence of combination of evidence-based medical therapies in patients with recent history of ACS in primary care setting

Head :Amelineau Élisabeth, Bristol-Myers Squibb  
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 09/05/2017 | Version : 2 | ID : 139

## General

### Identification

Detailed name Persistence of combination of evidence-based medical therapies in patients with recent history of ACS in primary care setting

Sign or acronym PREVENIR 5

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL N° 833542 version 12

### General Aspects

Medical area Cardiology

Keywords Secondary prevention, care, persistence

### Scientific investigator(s) (Contact)

Name of the director Amelineau

Surname Élisabeth

Address 3, rue J. Monier - 92500 Rueil Malmaison

Phone +33 (0)1 58 83 60 00

Email elisabeth.amelineau@bms.com

Unit Bristol-Myers Squibb

Name of the director Schmidely

Surname Nathalie

Address 3, rue J. Monier - 92500 Rueil Malmaison

Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb

## Collaborations

## Funding

Funding status	Private
----------------	---------

Details Bristol-Myers Squibb France

## Governance of the database

Sponsor(s) or organisation(s) responsible Bristol-Myers Squibb France (BMS)

Organisation status Private

## Additional contact

## Main features

## Type of database

Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	random sampling in clusters

## Database objective

Main objective	Describe the persistence of secondary prevention therapeutics, between 3 and 30 months after hospitalization for a first acute coronary syndrome (ACS), in patients monitored by general practitioners
Inclusion criteria	Patient $\geq 18$ years, outpatient seen in a general practice consultation, hospitalized in 2004 or 2005

for a 1st ACS

## Population type

Age  
Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered Sick population

Gender  
Male  
Woman

Geography area National

Detail of the geography area Metropolitan France

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY) 2006

Date of last collection (YYYY or MM/YYYY) 2007

### Size of the database

Size of the database (number of individuals) [1000-10 000[ individuals

Details of the number of individuals 5111

### Data

Database activity Data collection completed

Type of data collected  
Clinical data  
Biological data

Clinical data (detail) Direct physical measures

Biological data (detail) Total cholesterol, LDL chol, HDL chol, Triglycerides, fasting glucose

Presence of a biobank No

Health parameters studied Health care consumption and services

Care consumption (detail)

Medicines consumption

## Procedures

Data collection method

Paper CRF

Participant monitoring

No

Links to administrative sources

No

## Promotion and access

### Promotion

Link to the document

[http://www.ncbi.nlm.nih.gov/pubmed/?term=PREVENIR+AND+Amelineau+E\[Author\]](http://www.ncbi.nlm.nih.gov/pubmed/?term=PREVENIR+AND+Amelineau+E[Author])

### Access

Terms of data access (charter for data provision, format of data, availability delay)

Publications

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only